Health Highlights: July 11, 2018
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
Lawsuits Alleging Roundup Causes Cancer Can Move Forward: Judge
A judge's ruling means that hundreds of lawsuits alleging Roundup weed killer caused a cancer called non-Hodgkin's lymphoma can move forward.
U.S. District Judge Vince Chhabria said Tuesday that plaintiffs could present expert testimony linking the product to the cancer, the Associated Press reported.
While evidence that glyphosate -- the active ingredient in Roundup -- can cause non-Hodgkin's lymphoma is "rather weak," the opinions of the three experts are not "junk science" that should be excluded from a trial, Chhabria ruled.
While the decision means the lawsuits can move forward, the judge noted that it could be a "daunting challenge" to convince him to allow a jury to hear testimony that glyphosate was responsible for individual cancer cases, the AP reported.
Lawsuits allege that Roundup maker Monsanto long knew about the cancer risk associated with the week killer but did not warn people. There are hundreds of lawsuits in state and federal courts, and Chhabria is handling more than 400 of them.
"Moving forward, we will continue to defend these lawsuits with robust evidence that proves there is absolutely no connection between glyphosate and cancer," Monsanto Vice President Scott Partridge said in a statement. "We have sympathy for anyone suffering from cancer, but the science clearly shows that glyphosate was not the cause."
Many government regulators say there is no link between cancer and glyphosate, the AP reported.
Pfizer Temporarily Holds Off on Drug Price Hikes
Pharmaceutical company Pfizer says it's holding off on U.S. price increases it introduced on July 1, but will eventually restore those price hikes.
Pfizer CEO Ian Read discussed the matter Tuesday with President Donald Trump and Health Secretary Alex Azar, the Associated Press reported.
After the meeting, Pfizer issued a statement saying Read agreed to "defer the company's price increases that were effective on July 1 to give the president an opportunity to work on his blueprint to strengthen the healthcare system."
But Pfizer said it will "return these prices to their pre-July 1 levels as soon as technically possible," the AP reported.
On Monday, Trump complained about the price increases. After Tuesday's meeting, he tweeted that Pfizer is "rolling back price hikes, so American patients don't pay more."
Chronic Pain Patients Ask FDA to Ease Opioid Prescribing Restrictions
Patients with chronic pain want the U.S. Food and Drug Administration to ease restrictions that make it difficult for them to get opioid pain medicines.
The FDA is encouraging people to use other pain control methods as it tries to combat the nation's opioid epidemic.
At a meeting this week, several dozen patients told FDA officials about their pain and how they struggled to deal with it, NBC News reported.
One of them was Mariann Farrell of Pittsburgh, who said she has a number of conditions, including fibromyalgia and pain that can linger after shingles.
"Suicide is always an option for us," she said.
Another patient was Sandra Flores, a former emergency room nurse from Tucson, Arizona who two years ago was diagnosed with an inflammation of the membranes protecting the brain, spine and nerve endings. She said she can longer find a doctor to prescribe opioids for her pain, NBC News reported.
"I am seeing the true face of medicine," Flores said. "Now they are throwing me in the trash."
Federal health officials point to overprescribing of opioids as a major cause of the nation's opioid epidemic. Last year, the CDC said the number of prescriptions for opioids tripled between 1999 and 2015, NBC News reported.
The CDC issued guidelines recommending that doctors reduce opioid prescriptions and suggesting patients try anything else before asking for opioids.
Those alternatives include non-steroidal anti-inflammatory drugs (NSAIDs) such as acetaminophen, ibuprofen or naproxen, ice, physical therapy and massage. The CDC also says patients may have to change their expectations about living with pain.
In addition to federal measures, at least 28 states have limits on opioid prescriptions, according to the National Conference of State Legislatures, and other states have prescription drug monitoring programs to detect health care providers writing too many opioid prescriptions, NBC News reported.
"We don't want to perpetuate practices that led to the misuse of these drugs, and the addiction crisis. At the same time, we don't want to act in ways that are poorly targeted, and end up disadvantaging legitimate patients," FDA Commissioner Dr. Scott Gottlieb said in a statement.
"In most circumstances, opioids should only be used for the treatment of acute pain and prescribed for short durations of time," he noted.
"However, the FDA is aware that there are certain circumstances -- such as in the treatment of metastatic cancer pain and the episodic treatment of migraine pain -- where the drugs are administered over longer periods. In select patients and for certain medical conditions, opioids may be the only drugs that provide relief from devastating pain," Gottlieb said, NBC News reported.
© 2020 HealthDay. All rights reserved.
Posted: July 2018
Read this next
TUESDAY, Oct. 20, 2020 -- As the air people breathe gets dirtier, their odds for serious neurological disorders such as Parkinson's disease, Alzheimer's and other dementias rises,...
MONDAY, Oct. 19, 2020 -- New parents preparing a bottle for their baby should know the infant may ingest unwanted microplastics along with the nourishing formula, a new study...
TUESDAY, Oct. 6, 2020 -- The sting of fire ants can be painful and even deadly -- and the threat rises during fall across the southeastern United States. At this time of year,...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.